Access restrictions apply.Some or all content stored offsite.
Container | Contents | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Part II: Subject File, 1902-2012 (continued) | |||||||||||||
BOX II:115 | Birth defects/reviews, 1976, 1986-1990 | ||||||||||||
BOX II:115 | Birth surveys, 1963-1999, undated | ||||||||||||
(4 folders) | |||||||||||||
BOX II:115 | Breast milk, drugs in, 1947-1993, 2001, undated | ||||||||||||
(2 folders) | |||||||||||||
BOX II:116 | Bromocryptine, 1977-1985 | ||||||||||||
BOX II:116 | Bureau of Drugs, U.S. Food and Drug Administration | ||||||||||||
BOX II:116 | Clinical Investigator Stratified Surveillance Strategy, 1976-1980, undated | ||||||||||||
BOX II:116 | Deputy director, 1979-1982 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:116 | Caffeine, 1966, 1978-1982, undated | ||||||||||||
BOX II:116 | Carcinogenesis/teratology, 1963-1983, undated | ||||||||||||
BOX II:116 | Carrisyn/Carrington Laboratories, Dallas, Tex., 1986-1996 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:116 | Celebrex/Vioxx, 1999-2002 | ||||||||||||
BOX II:117 | Center for Drug Evaluation and Research, U.S. Food and Drug Administration | ||||||||||||
BOX II:117 | General, 1997-2000, undated | ||||||||||||
BOX II:117 | Reports, 1992-1995 | ||||||||||||
(3 folders) | |||||||||||||
BOX II:117 | Research Steering Committee | ||||||||||||
BOX II:117 | 1987-1988 | ||||||||||||
(3 folders) | |||||||||||||
BOX II:118 | 1990-1991 | ||||||||||||
BOX II:118 | Time reporting system, 1997-1999 | ||||||||||||
BOX II:118 | Chelation therapy, 2001 | ||||||||||||
BOX II:118 | Chick embryo studies, 1962-1972 | ||||||||||||
BOX II:118 | Chloramphenicol (Chloromycetin), 1962-1967, 1996-1997 | ||||||||||||
BOX II:118 | Chymopapain (Discase), 1973-1976, 1984, 1997-2000 | ||||||||||||
BOX II:118 | Chymotrypsin See Container II:140, Enzymes | ||||||||||||
BOX II:118 | Clinical Investigator Conflict of Interest Task Force, U.S. Food and Drug Administration | ||||||||||||
BOX II:118 | 1987-1991 | ||||||||||||
(3 folders) | |||||||||||||
BOX II:118 | 1992 | ||||||||||||
(1 folder) | |||||||||||||
BOX II:119 | (1 folder) | ||||||||||||
BOX II:119 | 1993-2000, undated | ||||||||||||
BOX II:119 | Clinical trials, 1981, 1990, 1999, undated | ||||||||||||
BOX II:119 | Clomiphene (Clomid), 1961-1989, undated | ||||||||||||
BOX II:119 | Close, John H., 1977-1978, 1999 | ||||||||||||
BOX II:119 | Cobalt summary, Ray D. Uphoff and Albert L. Maduska, 1966, undated | ||||||||||||
BOX II:119 | Cocaine, 1986-1997, undated | ||||||||||||
BOX II:119 | Colestipol, 1971-1974 | ||||||||||||
BOX II:119 | Complementary and alternative medicine, 1996-2001, undated | ||||||||||||
BOX II:119 | Compliance Policy Guides Manual (partial), microfiche, 1985 | ||||||||||||
Microfiche shelf no. 22,656 | |||||||||||||
BOX II:119 | Compliance Program, evaluations reports, 1975-1977 | ||||||||||||
BOX II:119 | Computer-Assisted New Drug Applications | ||||||||||||
BOX II:119 | General, 1980, 1988-1990, undated | ||||||||||||
BOX II:119 | Guidance manual, 1992 | ||||||||||||
BOX II:119 | Confidentiality statute See Containers II:188-II:189, Privacy Act/Confidentiality statute | ||||||||||||
BOX II:120 | Conflict of interest regulations, 1976-1978, circa 1993 | ||||||||||||
BOX II:120 | Congenital malformations review papers, 1957-1985, undated | ||||||||||||
(5 folders) | |||||||||||||
BOX II:120 | Congressional | ||||||||||||
BOX II:120 | Hearings | ||||||||||||
BOX II:120 | House of Representatives | ||||||||||||
BOX II:120 | Commission on the Federal Drug Approval Process (McMahon Commission) | ||||||||||||
BOX II:120 | 1981-1988 | ||||||||||||
(4 folders) | |||||||||||||
BOX II:121 | 1996-1999, undated | ||||||||||||
(2 folders) | |||||||||||||
BOX II:121 | Drug Safety, 1964 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:121 | Fraud in biomedical research, 1981 | ||||||||||||
BOX II:121 | National Ambient Air Quality Standards, 1984 | ||||||||||||
BOX II:121 | Use of Advisory Committees by the U.S. Food and Drug Administration (Fountain Committee), 1982, 1997-1999 | ||||||||||||
BOX II:121 | Senate | ||||||||||||
BOX II:121 | Interagency Coordination in Drug Research Regulation | ||||||||||||
BOX II:121 | 1961 See Oversize | ||||||||||||
BOX II:121 | 1962 | ||||||||||||
BOX II:121 | Mar.-May | ||||||||||||
BOX II:121 | Aug. | ||||||||||||
(1 folder) | |||||||||||||
BOX II:122 | (4 folders) | ||||||||||||
BOX II:122 | 1963 | ||||||||||||
BOX II:122 | Investigation of drug industry (Estes Kefauver), 1960-1964, 1997 | ||||||||||||
BOX II:122 | United States Government and the future of international medical research, 1961 | ||||||||||||
BOX II:123 | Miscellany | ||||||||||||
BOX II:123 | Questions, undated | ||||||||||||
BOX II:123 | Testimony, 1960-1961, 1970, 2000 | ||||||||||||
(4 folders) | |||||||||||||
BOX II:123 | Reports | ||||||||||||
BOX II:123 | House of Representatives, circa 1963-1966 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:123 | Office of Technology Assessment, 1974-1976 | ||||||||||||
BOX II:124 | Senate, 1960-1966 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:124 | Consumer information publications by U.S. Food and Drug Administration, 1956-1988, undated | ||||||||||||
(4 folders) | |||||||||||||
BOX II:124 | Contracts and Grants Review Committee, 1988-1989 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:124 | Contracts for studies | ||||||||||||
BOX II:124 | Auerbach Associates, FDA 72-63, 1972 | ||||||||||||
BOX II:125 | Center for Disease Control, possible contract, 1973 | ||||||||||||
BOX II:125 | Children’s Hospital Research Foundation, Cincinnati, Ohio | ||||||||||||
BOX II:125 | FDA 68-44, FDA 70-7, FDA 71-11 | ||||||||||||
BOX II:125 | 1967-1970 | ||||||||||||
(7 folders) | |||||||||||||
BOX II:126 | 1971-1976 | ||||||||||||
(5 folders) | |||||||||||||
BOX II:126 | FDA 641-8-131, 1968 | ||||||||||||
BOX II:126 | Mayo Foundation, Rochester, Minn., FDA 72-339, FDA 7837-73(B) | ||||||||||||
BOX II:126 | 1971-1973 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:127 | 1974-1976 | ||||||||||||
BOX II:127 | National Academy of Sciences-National Research Council, FDA 70-22, FDA 71-52, FDA 72-1, 1970-1974, 1999 | ||||||||||||
(2 folders) | |||||||||||||
BOX II:127 | University of Miami, Miami, Fla. | ||||||||||||
BOX II:127 | FDA 66-210, 1967-1968 | ||||||||||||
BOX II:127 | FDA 67-54, FDA 68-47, FDA 69-34 | ||||||||||||
BOX II:127 | 1967-1970 | ||||||||||||
(4 folders) | |||||||||||||
BOX II:128 | 1971-1975, 1999 | ||||||||||||
BOX II:128 | FDA 641-8-157, 1968-1973 | ||||||||||||
BOX II:128 | Control and dispensing of drugs, 1960-1963, 1996, undated | ||||||||||||
BOX II:128 | Coulston Foundation, Alamogordo, N. Mex./Frederick Coulston, 1966, 1992, 1998-2000 | ||||||||||||
BOX II:128 | Daroil, 1964-1965 | ||||||||||||
BOX II:128 | Darvon, 1979-1980 See also Container II:139, Eli Lilly and Co. Task Group | ||||||||||||
BOX II:128 | Data handling of scientific information, 1959-1964, 1995-1999, undated | ||||||||||||
BOX II:128 | Day, J. Edward, 1965, 1996, undated | ||||||||||||
BOX II:128 | Day, Paul L., 1961, 1999, undated | ||||||||||||
BOX II:128 | Definition of terms “drug” and “new drug,” undated | ||||||||||||
BOX II:128 | Defoliants and herbicides See Container II:186, Pesticides and environmental hazards | ||||||||||||
BOX II:128 | DeMarco, Peter See Container II:189, Procaine with polyvinylpyrrolidone (PVP) | ||||||||||||
BOX II:128 | Depo-Provera, 1966, 1975-1984, undated | ||||||||||||
Next Page » |